Plus Radiance gets ROR1 ADC from Cspc, Astrazeneca buys Fibrogen’s China subsidiary and more

Upstream regulators of ion channel expression or function are an emerging frontier for novel pain targets

Plus: Pair of cash-rich biotechs agree to combine, and Australian radiopharma company Advancell follows venture round by expanding Lilly relationship

Plus: Readouts from Sanofi-Teva, Bicycle and more

Positive data from second Phase III trial of veligrotug in thyroid eye disease; this time in chronic setting

Plus: Results from Relay, Centessa, Viridian, Amgen and more

Plus: Readouts from Avidity, Apellis/Sobi, Levicept and Merck

With CEO Shao-Lee Lin leaving, the company said it’s aiming to preserve cash resources, with a series of decision-driving clinical catalysts on the way

Plus readouts for Nanoscope, Axsome, Chugai, Acelyrin and Nkarta